Andrew Warren

Join us on July 31st for our webinar to learn how the Newomics platform accelerates the direct mass analysis of ADCs.

6

Great to catch up with Ron Leuty at San Francisco Business Times at #BIO2024: When Moonwalk Biosciences Inc. CEO Alex Aravanis MD PhD started his presentation at the BIO convention in San Diego earlier this week, he saw a standing-room-only crowd, and after his 15-minute talk he was peppered with questions. In more formal meetings with potential partners, Aravanis faced more questions. "I think there's a lot of people who are curious about (epigenetics)" — how DNA modifications can be passed cell to cell — "curious about the capabilities, how mature it is," Aravanis said. "In the partnering meetings, there're folks who have an immediate use for it, and there are folks who said, 'Look, we reached out to you because we realized this is an exciting new area.'" The ability to spread a company's scientific message with hundreds, if not thousands, of people in a few days is why companies come to the Biotechnology Innovation Organization's annual convention, which closes today in San Diego. More than 20 Bay Area life sciences companies were scheduled among the scores making formal presentations in tiny "theaters" on the convention's exhibit floor, such as South San Francisco's Moonwalk, or in BIO's "Startup Stadium." Read the article (subscription required): https://lnkd.in/eTEdgDEa

28

DRAGEN V4.3…making huge strides with difficult genes. New specialized callers enable genotyping of genes such as PMS2, NEB, IKBKG etc. in segmental duplication regions

20

Following up on the excitement of the launch of IRO last week. We can now share highlights of the biological data CTMC has produced as they used our pre-commercial instrument. Compared to their current manufacturing process, and across 9 runs carried out on 2 different sites IRO has demonstrated: 🧫 A higher average transduction efficiency of 69% vs 45% 🧫 Consistently higher cell yields 🧫 A rapid process transfer: taking just weeks, rather than the industry's usual 6-9 months This just starts to show the potential of the IRO platform to address some of the challenges in the manufacturing of these therapies. #automatingbetterbiology #ISCT2024 #celltherapy #manufacturingbrighterfutures

19

We’re fortunate to have leading computational biology experts like Aviv Regev advancing our understanding of cancer like never before. At #AACR24, she shared the importance of connection in drug discovery – from the data to the lab to the clinic. #AI is fueling this connection. I’m excited about the strides we’ve made at Genentech using AI across many parts of our organization, including applying it to accelerate drug discovery and development. I’m looking forward to seeing how AI, computation, data science and digital technology continue to enhance our ability to improve patient care and bring innovative medicines to patients faster. #DigitalTransformation https://lnkd.in/g4Mh9vCc

688

7 Comments

At PROTEINA, our recent publication on bioRxiv demonstrates the groundbreaking capabilities of the Single molecule Protein Interaction Detection (SPID) platform in advancing antibody development with finely-tuned affinities. I’d like to highlight two groundbreaking aspects from this study that are particularly significant: 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐌𝐨𝐝𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐂𝐃𝐑𝐬: Our targeted edits within the Complementarity Determining Regions (CDRs) of antibodies have led to the discovery of affinity-enhancing mutations. These modifications have successfully produced sub-nanomolar affinity candidates, setting a new benchmark for antibody affinity maturation. 𝐇𝐢𝐠𝐡-𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧: The ability of PROTEINA’s SPID platform to rapidly characterize over 3,000 antibodies weekly is revolutionizing our understanding of antibody-antigen interactions. This capability is crucial for accelerating the development of tailored therapeutic interventions.   Almost forgot to mention this! Keep an eye on the future contributions of PROTEINA’s Jihye Jo well!

26

4 Comments

Nikki Carter, our Director of Commercial Organoid Innovation, leverages decades of experience in large pharmaceutical companies to help researchers optimize organoid-based drug discovery and high-throughput screening programs. Check out her latest published perspectives on these topics and more: https://ow.ly/Xxm350SzKrR. ✏️ A Three-Pillar Approach to Driving Organoid Adoption in Drug Discovery: https://ow.ly/y6sq50SzKrQ ✏️ Patient-Derived Organoids in Disease Modeling: https://ow.ly/RAgJ50SzKrS #3dbiology #3dcellculture #organoids #drugdiscovery #drugscreening #drugdevelopment #diseasemodeling #labautomation #ai #machinelearning #deeplearning #highcontentimaging #highcontentscreening #scienceandtechnology #pharma #geneeditting #cellculture #pdo #imageanalysis

25

2 Comments

Thank you Robert Plenge for a really interesting and dynamic conversation. Just great to talk from the science to the strategy, with a conversation that digs into the three tenets of the BMS Research framework - Picking the right target - Choosing the right modality - Ensuring a clear path to clinical POC And we covered a lot of ground, from the science behind the Karuna acquisition to why taking CAR T cells into autoimmunity could be a game change. Other highlights: - how causal biology underpins the strategy - why First in Class is so important - what's behind the new chapter in ADCs and more! Here on #TheBioCenturyShow BioCentury Inc. Bristol Myers Squibb #CART #ADC #causalbiology #Firstinclass

10

We are pleased to share details from a paper co-authored by Crescendo scientists and the Resolian team, published earlier this week in Bioanalysis Zone. In the development of novel therapeutics, establishing robust and reliable assays to understand the pharmacokinetic (PK) properties of a drug in patients is crucial. Bispecific antibody fragments present unique challenges due to the multiple targets and often reduced molecular size, which increases the complexity of assay development.   Our scientists have developed a method to quantify CB307, our first-in-class Humabody® VH bispecific targeting PSMA and CD137 in blood. This method is already being used to support our Phase 1b POTENTIA clinical trial. In this paper, we share our findings and the method development process as a case study to help the broader scientific community overcome similar challenges in developing antibody fragment-based therapeutics.   To read the full paper, visit: https://lnkd.in/e9Z-vpZN   #Cancer #Biotech #Therapeutics

30

NAMI Oregon is proud to join Neurocrine Biosciences in supporting #TDAwarenessWeek, running from May 5-11. Tardive Dyskinesia (TD) is a condition characterized by persistent, involuntary movements affecting various parts of the body, such as the face, torso, limbs, and fingers or toes. These movements can vary from rapid and jerky to slow and writhing, significantly impacting those affected by TD. TD is often associated with prolonged use of antipsychotic medication, which may be necessary to treat mental illnesses like major depressive disorder and bipolar disorder. Approximately 600,000 Americans live with TD, and around 65% of them are undiagnosed. Let's raise awareness together and support those living with TD during #TDAwarenessWeek. Learn more at https://lnkd.in/g-atBE4x or www.TalkAboutTD.com.

1

🌟 Exciting Learning Opportunity for Chemists and Researchers! 🌟 Join us for an enlightening webinar titled "Enhancing Synthesis Workflows Through Computer-Assisted Retrosynthesis," hosted by SelectScience and featuring Dr. Ewa Gajewska, Head of Product Management for SYNTHIA™ Retrosynthesis Software at Merck. 📅 Date: June 21, 2024 ⏰ Time: 17:00 CET 🔗 Registration: https://lnkd.in/dWwBxK9W Why Attend? • Discover the Power of SYNTHIA™: Learn how SYNTHIA™ leverages advanced algorithms and chemical databases to transform drug discovery and chemical development processes. • Customize Your Workflow: Gain insights on customizing search parameters within SYNTHIA™ to optimize synthetic routes, reducing manual efforts and accelerating outcomes. • Address Synthetic Challenges: Understand the common challenges in synthetic chemistry and how SYNTHIA™ addresses them, paving the way for future advancements. This webinar is a must-attend for: • Drug Discovery Chemists • Cheminformaticians • Medicinal Chemists • Process Chemists • Organic Chemists Participants will also have the opportunity to request a certificate of attendance for continuing education purposes. Don’t miss out on this chance to enhance your knowledge and skills in drug discovery and synthetic chemistry. Secure your spot today! #Chemistry #DrugDiscovery #Webinar #SYNTHIA #SelectScience #Education #ProfessionalDevelopment #TeamMerck

3

1 Comment

Attention Seattle biotech teams! Come and connect with other local biotechs, suppliers and of course our scientist.com team! Get in touch with Natalie Duner for the registration link! You will be able to - Meet top-notch suppliers that are a part of the Scientist.com network - Find innovative and research savvy partners for your upcoming projects - Network with fellow biotech professionals Yes. There will be FREE lunch! 🍽️ #seattle #biotech #outsourcing #lunchandlearn

As someone who had the privilege of being part of the pioneering team that established the Institute for Personalized Cancer Therapy at MD Anderson Cancer Center back in 2011, I am both proud of the strides we have made and concerned about the pace at which precision oncology has been adopted. When we embarked on this journey, we were driven by the vision of tailoring cancer treatment to each patient's unique genetic profile, believing it would revolutionize cancer care within a decade. Yet, as we find ourselves in 2024, it's clear that while the potential of precision oncology is undeniable, its integration into mainstream clinical practice is still lagging behind. This is not just a matter of technology or science but also of policy, education, and healthcare infrastructure. Real-world evidence shows that the benefits of precision oncology are profound, but access to these advanced therapies remains uneven. Let's continue to push for a future where every cancer patient has access to personalized, effective treatments. The journey is far from over, and it's on all of us to ensure that precision oncology is not just a promise but a reality for all. #PrecisionOncology #CancerTreatment #HealthcareInnovation #PersonalizedMedicine https://lnkd.in/gc3tSxqF

23

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

Our GenAI for sequence and structure generation of paratopes in action

13

Element Biosciences has raised an additional $277 million in private financing to support commercialization of its benchtop DNA sequencer and an instrument launch as the company takes on market leader Illumina. Founded in 2017, Element is part of the race to drive down the cost of DNA sequencing. It’s also pushing into multiomics, which includes RNA and protein data. The haul brings Element’s fundraising total to $680 million. CEO Molly He said Element is in “no rush to become a public company.... #biotech #biotechnology #lifescience #lifesciences #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #seriesD #seriesfinancing #commercialization #DNAsequencing #commerciallaunch #multiomics #RNA #protein #680m #benchtop

59

Don’t miss this opportunity at the Gene Therapy Initiative 1st Annual Symposium on September 19, 2024 to engage our thriving San Diego community of researchers, life sciences, biotechnology and pharmaceutical companies in the gene therapy space. The Gene Therapy Initiative (GTI) Symposium will convene researchers and industry experts to share the latest scientific findings and facilitate new partnerships with the goal of expediting the delivery of stem cell and gene therapy treatments, especially for patients with rare genetic diseases. Program Highlights: *Exploratory talks on innovative gene modifying therapeutics and optimization of existing tools. *Updates on gene therapies that are the subject of academic research and commercial development. *Induced Pluripotent Stem-cell-based disease models to test gene therapies. *Interactive panel on resources and collaboration for developing therapies for rare diseases. *Opportunity to learn about 2024 GTI seed grant funded projects. *Poster session featuring faculty and student research. *Networking hour to foster connectivity amongst attendees. Please note, there is NO CME for this symposium.   For more information and to register, go to: https://lnkd.in/gJuEP_Kv #GeneTherapy #genetherapies #RNAtechnologies #ExVivoGeneTherapy #AAVgenetherapy #research #science #lifesciences #biotechnology #scientificmeeting

12